Co-Administration of Soy Isoflavones and Vitamin D in Management of Irritable Bowel Disease.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

Both soy isoflavones and vitamin D can modulate estrogen receptors in the colonic smooth muscles.

The aim of this study was to investigate the effects of soy isoflavones, vitamin D and their probable interactions in women with IBS.

Who Took Part

According to the abstract, 100 women were involved.

PubMed indexes the participants as teenagers, young adults, adults, middle-aged adults and older adults.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

The women were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

Blinding on both sides kept the women and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.

A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.

The clinical outcomes were IBS symptoms severity scores (IBS-SSS), disease- specific quality of life (IBS-QOL) and total score (IBS-TS) that evaluated at weeks 0, 6, and 10, and compared to each other.

What Was Measured

The subject headings attached to it are Irritable Bowel Syndrome, Isoflavones, Placebo Effect, Quality of Life, Glycine max, Surveys and Questionnaires and Vitamin D.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 100 women.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2016 (PloS one), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.